Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey G. Supko, Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01CA105689 (SUPKO, JEFFREY G) Jul 22, 2004 - Dec 31, 2008
    Phamacokinetics Center for the NABTT CNS Consortium
    Role: Principal Investigator
  2. N01CM097619 (FELLER, DENNIS R) Apr 14, 1989 - Apr 13, 1992
    Role: Co-Principal Investigator
  3. N01CM073701 (SUPKO, JEFFREY G) Jun 1, 1987 - May 31, 1992
    Role: Principal Investigator
  4. P30CA006516 (GLIMCHER, LAURIE HOLLIS) Nov 30, 2021
    Dana-Farber/Harvard Cancer Center
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Stamou MI, Chen C, Wander SA, Supko JG, Juric D, Bardia A, Wexler DJ. Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. JCO Precis Oncol. 2022 06; 6:e2100428. PMID: 35700410; PMCID: PMC9384915.
    Citations:    Fields:    Translation:Humans
  2. Lopez BGC, Kohale IN, Du Z, Korsunsky I, Abdelmoula WM, Dai Y, Stopka SA, Gaglia G, Randall EC, Regan MS, Basu SS, Clark AR, Marin BM, Mladek AC, Burgenske DM, Agar JN, Supko JG, Grossman SA, Nabors LB, Raychaudhuri S, Ligon KL, Wen PY, Alexander B, Lee EQ, Santagata S, Sarkaria J, White FM, Agar NYR. Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2022 01 05; 24(1):64-77. PMID: 34383057; PMCID: PMC8730776.
    Citations: 1     Fields:    Translation:Humans
  3. Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 04; 126(7):1027-1036. PMID: 34887522; PMCID: PMC8980096.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  4. Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, Bardia A. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103. PMID: 34349115.
    Citations: 2     
  5. Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505. PMID: 34228505.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  6. Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA. Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98. PMID: 33373063; PMCID: PMC7954938.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  7. Duska LR, Krasner CN, O'Malley DM, Hays JL, Modesitt SC, Mathews CA, Moore KN, Thaker PH, Miller A, Purdy C, Zamboni WC, Lucas AT, Supko JG, Schilder RJ. A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2021 03; 160(3):688-695. PMID: 33390325.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  8. Do KT, O'Sullivan Coyne G, Hays JL, Supko JG, Liu SV, Beebe K, Neckers L, Trepel JB, Lee MJ, Smyth T, Gannon C, Hedglin J, Muzikansky A, Campos S, Lyons J, Ivy P, Doroshow JH, Chen AP, Shapiro GI. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 12; 86(6):815-827. PMID: 33095286.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  9. Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, Ye X. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. Neuro Oncol. 2020 10 14; 22(10):1422-1424. PMID: 32506123; PMCID: PMC7566550.
    Citations: 8     Fields:    Translation:Humans
  10. Tripathi A, Supko JG, Gray KP, Melnick ZJ, Regan MM, Taplin ME, Choudhury AD, Pomerantz MM, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff PW, Sweeney CJ, Harshman LC. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131. PMID: 32943461.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  11. McDannold N, Zhang Y, Supko JG, Power C, Sun T, Vykhodtseva N, Golby AJ, Reardon DA. Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. Sci Rep. 2020 05 29; 10(1):8766. PMID: 32472017.
    Citations: 6     Fields:    Translation:Animals
  12. McDannold N, Zhang Y, Supko JG, Power C, Sun T, Peng C, Vykhodtseva N, Golby AJ, Reardon DA. Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. Theranostics. 2019; 9(21):6284-6299. PMID: 31534551.
    Citations: 29     Fields:    Translation:Animals
  13. Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229. PMID: 30765148.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  14. Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07. PMID: 29882250; PMCID: PMC6286224.
    Citations: 2     Fields:    
  15. Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 2017 06 01; 19(6):845-852. PMID: 28371832; PMCID: PMC5464434.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  16. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575. PMID: 27663390; PMCID: PMC5464374.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  17. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017 07 01; 23(13):3307-3315. PMID: 28053023; PMCID: PMC5496796.
    Citations: 92     Fields:    Translation:HumansCTClinical Trials
  18. Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 04; 102(4):719-727. PMID: 28034990.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  19. Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clin Cancer Res. 2017 Jul 15; 23(14):3520-3528. PMID: 28031425.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  20. Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579. PMID: 27826680.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  21. Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE, Burke JN, Tamang DL, Yang M, Jones SS, Wheeler CA, Markelewicz RJ, Raje NS. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016 Nov; 17(11):1569-1578. PMID: 27646843.
    Citations: 76     Fields:    Translation:HumansCTClinical Trials
  22. Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306. PMID: 27421044.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  23. Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res. 2016 Oct 01; 22(19):4786-4796. PMID: 27154916.
    Citations: 47     Fields:    Translation:HumansCellsCTClinical Trials
  24. Albrecht BK, Gehling VS, Hewitt MC, Vaswani RG, Côté A, Leblanc Y, Nasveschuk CG, Bellon S, Bergeron L, Campbell R, Cantone N, Cooper MR, Cummings RT, Jayaram H, Joshi S, Mertz JA, Neiss A, Normant E, O'Meara M, Pardo E, Poy F, Sandy P, Supko J, Sims RJ, Harmange JC, Taylor AM, Audia JE. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. J Med Chem. 2016 Feb 25; 59(4):1330-9. PMID: 26815195.
    Citations: 55     Fields:    Translation:HumansAnimalsCells
  25. Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90. PMID: 26549586.
    Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
  26. Blakeley JO, Grossman SA, Mikkelsen T, Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia Ribas I, Supko JG, Desideri S, Ye X. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neurooncol. 2015 Oct; 125(1):123-31. PMID: 26285766; PMCID: PMC4869687.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  27. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. PMID: 25079173.
    Citations: 90     Fields:    Translation:HumansCTClinical Trials
  28. Sloan AE, Nock CJ, Supko J, Ye X, Takebe N, Rich J, Prados M, Grossman S. Targeting glioma initiating cells in gbm: abtc-0904, a randomized phase 0/ii study targeting the sonic hedgehog-signaling pathway. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii46. PMID: 25165343.
  29. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, Pontiggia L, O'Dwyer PJ, Davis LE, Amaravadi RK. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014 Aug; 10(8):1359-68. PMID: 24991840.
    Citations: 237     Fields:    Translation:HumansCTClinical Trials
  30. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53. PMID: 24625776; PMCID: PMC4122326.
    Citations: 139     Fields:    Translation:HumansCTClinical Trials
  31. Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX. Phase 1 study of N(1),N(11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1305-14. PMID: 24121453.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  32. Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013 Jul 25; 122(4):507-14. PMID: 23741010; PMCID: PMC3724190.
    Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
  33. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. PMID: 23645694.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  34. Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8. PMID: 23580238.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  35. Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res. 2013 Apr 01; 19(7):1873-83. PMID: 23515411.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  36. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66. PMID: 23362324.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  37. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. PMID: 23358966.
    Citations: 102     Fields:    Translation:HumansCells
  38. Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2013 Apr; 15(4):490-6. PMID: 23328813.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  39. Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F. A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb; 111(3):347-53. PMID: 23232808.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  40. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1602-8. PMID: 22878749.
    Citations: 70     Fields:    Translation:HumansCTClinical Trials
  41. Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget. 2012 Aug; 3(8):869-81. PMID: 22935625.
    Citations: 50     Fields:    Translation:HumansAnimalsCells
  42. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319.
    Citations: 94     Fields:    Translation:HumansCTClinical Trials
  43. Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol. 2012 Apr; 14(4):511-7. PMID: 22323663.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  44. Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, Murphy GF, Dimitroff CJ. Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol. 2012 Feb; 132(2):410-20. PMID: 22158550.
    Citations: 27     Fields:    Translation:AnimalsCells
  45. Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, McGinn CM, Lanuti M, Tanabe KK. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther. 2012 Mar; 19(3):160-70. PMID: 22076044.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  46. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol. 2011 Dec; 13(12):1324-30. PMID: 21954442.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  47. Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, Denoyelle S, He X, Zvereva N, Supko JG, Chorev M, Halperin JA, Aktas BH. Chemical genetics identify eIF2a kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol. 2011 Jul 17; 7(9):610-6. PMID: 21765405.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  48. Peereboom DM, Rich JN, Supko JG, Lamborn K, Ye X, Sloan AE, Prados M, Grossman SA. A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS135. PMID: 28022896.
  49. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011 May; 10(5):806-16. PMID: 21421804.
    Citations: 90     Fields:    Translation:HumansAnimalsCells
  50. Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14093-8. PMID: 20660316.
    Citations: 103     Fields:    Translation:Humans
  51. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol. 2010 Nov; 100(2):261-8. PMID: 20449631.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  52. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010 Oct; 100(1):95-103. PMID: 20213332; PMCID: PMC3811025.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  53. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205. PMID: 19672973.
    Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
  54. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3. PMID: 20007809; PMCID: PMC2826760.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  55. Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol. 2010 Apr; 97(2):241-5. PMID: 19768386.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  56. Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1156-62. PMID: 19704336.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  57. Supko JG, Grossman SA, Peereboom DM, Chowdhary S, Lesser GJ, Nabors LB, Mikkelsen T, Desideri S, Batchelor TT. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2039. PMID: 27964617.
  58. Hu J, Wen PY, Abrey LE, Fadul C, Drappatz J, Salem N, Amato A, Carminati P, Supko J, Hochberg F. Phase II trial of oral gimatecan in adults with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2009. PMID: 27964558.
  59. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009 Feb; 52(2):169-76. PMID: 19065567.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  60. Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009 Jan 01; 15(1):374-81. PMID: 19118068.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  61. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol. 2009 Jan; 91(1):51-8. PMID: 18787762.
    Citations: 54     Fields:    Translation:HumansCTClinical Trials
  62. Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol. 2008 Aug; 10(4):608-16. PMID: 18577560.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  63. Hong DS, Kurzrock R, Supko JG, Lawrence DP, Wheler JJ, Meyer CJ, Mier JW, Andreeff M, Shapiro GI, Dezube BJ. Phase I trial with a novel oral NF-?B/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):3517. PMID: 27949759.
  64. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54. PMID: 18316568.
    Citations: 51     Fields:    Translation:HumansCTClinical Trials
  65. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008 Apr; 10(2):190-8. PMID: 18287342.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  66. Miao XS, Song P, Savage RE, Zhong C, Yang RY, Kizer D, Wu H, Volckova E, Ashwell MA, Supko JG, He X, Chan TC. Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood. Drug Metab Dispos. 2008 Apr; 36(4):641-8. PMID: 18180274.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  67. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19936-41. PMID: 18077425.
    Citations: 170     Fields:    Translation:HumansCells
  68. Akingbemi BT, Braden TD, Kemppainen BW, Hancock KD, Sherrill JD, Cook SJ, He X, Supko JG. Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat. Endocrinology. 2007 Sep; 148(9):4475-88. PMID: 17569756.
    Citations: 23     Fields:    Translation:AnimalsCells
  69. Srouji SS, Pagán YL, D'Amato F, Dabela A, Jimenez Y, Supko JG, Hall JE. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab. 2007 Apr; 92(4):1347-52. PMID: 17264175.
    Citations: 21     Fields:    Translation:Humans
  70. Berkenblit A, Eder JP, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):584-90. PMID: 17255281.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  71. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70. PMID: 17216531.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  72. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 2006 Dec 01; 107(11):2688-97. PMID: 17075878.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  73. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006 Nov 15; 107(10):2482-9. PMID: 17036355.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  74. Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 01; 12(17):5174-81. PMID: 16951236.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  75. Krasner CN, Seiden MV, Fuller AF, Roche M, Verrill CL, D'Amato F, Tretyakov O, Tyburski K, Matulonis UA, Supko JG. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5008. PMID: 27952185.
  76. Phuphanich S, Supko J, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J. Phase I trial of bortezomib in adults with recurrent malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1567. PMID: 27952496.
  77. Supko JG, He X, Sao N, D'Amato F, Blaszkowsky L, Clark JR, Shapiro GI, Bhargava P, Appleman LJ, Eder JP. Pharmacokinetics of PT523, a novel aminopterin analogue, in patients with solid tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2052. PMID: 27952674.
  78. Olson JJ, Blakeley JO, Grossman SA, Weingart J, Rashid A, Supko J. Differences in the distribution of methotrexate into high grade gliomas following intravenous administration, as monitored by microdialysis, are associated with blood brain barrier integrity. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1548. PMID: 27952560.
  79. Hochberg FH, Supko J, Amato A, Salem N, Carminati P, Wen P. Phase I trial and pharmacokinetic study of oral gimatecan in adults with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1559. PMID: 27952590.
  80. Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med. 2006 Apr 13; 354(15):1615-25. PMID: 16611953.
    Citations: 2     Fields:    Translation:Humans
  81. Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2006 Jul; 58(1):107-16. PMID: 16362299.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  82. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005 Oct 01; 104(7):1418-27. PMID: 16116597.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  83. Klein A, He X, Roche M, Mallett A, Duska L, Supko JG, Seiden MV. Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. Gynecol Oncol. 2006 Jan; 100(1):205-9. PMID: 16171852.
    Citations: 6     Fields:    Translation:Humans
  84. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005 Aug 20; 23(24):5484-92. PMID: 16110008.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  85. Olson JJ, Supko J, Phuphanich S, McKenzie E, Grossman SA. Intratumoral pharmacokinetics determined with microdialysis in a patient with glioblastoma multiforme following systemic administration of high dose methotrexate. J Clin Oncol. 2005 Jun; 23(16_suppl):1569. PMID: 27946960.
  86. Berkenblit A, Supko J, Ryan DP, Seiden MV, Nagai M, Bertin J, Dahl T, Dezube B, Eder JP. STA-4783 in combination with paclitaxel induces heat shock protein 70 (hsp70) in a phase I trial. J Clin Oncol. 2005 Jun; 23(16_suppl):2011. PMID: 27946827.
  87. Lesser GJ, Grossman SA, Carson K, Phupanich S, Batchelor T, Peereboom D, Nabors LB, Supko J, Hausheer F. Phase I study of karenitecin in the treatment of recurrent malignant gliomas (MG). J Clin Oncol. 2005 Jun; 23(16_suppl):1527. PMID: 27947141.
  88. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Does phenytoin does affect celecoxib pharmacokinetics in patients with newly diagnosed glioblastoma multiforme? J Clin Oncol. 2005 Jun; 23(16_suppl):2085. PMID: 27946645.
  89. Shapiro GI, Supko JG, Ryan DP, Appelman L, Berkenblit A, Craig AR, Jones S, Yagovane D, Li C, Eder J. Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):3042. PMID: 27945797.
  90. Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3417-24. PMID: 15867243.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  91. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer. 2005 Jan 20; 113(3):490-8. PMID: 15455390.
    Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
  92. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol. 2005 Jan; 7(1):32-40. PMID: 15701280; PMCID: PMC1871621.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  93. Peereboom D, Carson K, Lawson D, Lesser G, Supko J, Grossman S. A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1546. PMID: 28015471.
  94. Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2039. PMID: 28015627.
  95. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350(21):2129-39. PMID: 15118073.
    Citations: 3728     Fields:    Translation:HumansCells
  96. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15; 22(8):1480-90. PMID: 15084621.
    Citations: 90     Fields:    Translation:HumansCTClinical Trials
  97. Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res. 2004 Apr 01; 10(7):2222-30. PMID: 15073096.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  98. Eder JP, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs. 2004 Apr; 22(2):139-50. PMID: 14739662.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  99. Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer. 2004 Feb; 3(4):225-34. PMID: 15025795.
    Citations: 4     Fields:    Translation:Humans
  100. He X, Batchelor TT, Grossman S, Supko JG. Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 25; 799(2):281-91. PMID: 14670747.
    Citations: 1     Fields:    Translation:Humans
  101. Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004 Jan; 6(1):21-7. PMID: 14769136; PMCID: PMC1871974.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  102. Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003 Nov 01; 9(14):5178-86. PMID: 14613997.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  103. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8. PMID: 13678734.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  104. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003 Aug 15; 98(4):832-40. PMID: 12910529.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  105. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003 Aug 01; 9(8):2940-9. PMID: 12912940.
    Citations: 54     Fields:    Translation:HumansCTClinical Trials
  106. Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer. 2003 Jan 01; 97(1):148-54. PMID: 12491516.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  107. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84. PMID: 12228197.
    Citations: 50     Fields:    Translation:HumansCTClinical Trials
  108. Stokvis E, Rosing H, López-Lázaro L, Rodriguez I, Jimeno JM, Supko JG, Schellens JH, Beijnen JH. Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2002 Sep; 37(9):992-1000. PMID: 12271442.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  109. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 Oct; 50(4):309-19. PMID: 12357306.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  110. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res. 2002 Mar; 8(3):691-7. PMID: 11895897.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  111. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002 Mar; 8(3):641-61. PMID: 11895891.
    Citations: 88     Fields:    Translation:HumansAnimals
  112. Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist. 2002; 7(6):531-8. PMID: 12490740.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  113. Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001 Dec; 7(12):3942-9. PMID: 11751486.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  114. Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2001 Nov; 48(5):347-55. PMID: 11761451.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  115. Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67. PMID: 11571729.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  116. Supko JG, Garcia-Carbonero R, Puchalski TA, Malspeis L. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs. Cancer Chemother Pharmacol. 2001 Sep; 48(3):202-8. PMID: 11592341.
    Citations:    Fields:    Translation:AnimalsCells
  117. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ, Rollins BJ. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res. 2001 Jun; 7(6):1590-9. PMID: 11410495.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  118. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001 Feb; 7(2):231-42. PMID: 11234874.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  119. Ciordia R, Supko J, Gatineau M, Batchelor T. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing. Curr Oncol Rep. 2000 Sep; 2(5):445-53. PMID: 11122877.
    Citations: 2     Fields:    Translation:Humans
  120. Phillips LR, Malspeis L, Tubbs EK, Supko JG. Characterization of a novel degradation product of 2,2'-dithiobis[N-isoleucylbenzamide], an inhibitor of HIV nucleocapsid protein zinc fingers. J Pharm Biomed Anal. 2000 Aug 15; 23(2-3):395-402. PMID: 10933532.
    Citations:    Fields:    Translation:Cells
  121. Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol. 2000; 46(4):319-28. PMID: 11052630.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  122. Supko JG, Nair RV, Seiden MV, Lu H. Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma. J Pharm Biomed Anal. 1999 Dec; 21(5):1025-36. PMID: 10703971.
    Citations:    Fields:    Translation:Humans
  123. Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clin Cancer Res. 1999 Jun; 5(6):1299-305. PMID: 10389912.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  124. Sharpless JL, Supko JG, Martin KA, Hall JE. Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women. J Clin Endocrinol Metab. 1999 Feb; 84(2):688-94. PMID: 10022439.
    Citations: 9     Fields:    Translation:Humans
  125. Supko JG, Soglia JR, Nair RV. Assay for the quinocarmycin analog DX-52-1 in human plasma using high-performance liquid chromatography with automated column switching and low wavelength ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998 Sep 04; 714(2):341-53. PMID: 9766875.
    Citations:    Fields:    Translation:Humans
  126. Phillips LR, Wolfe TL, Malspeis L, Supko JG. Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection. J Pharm Biomed Anal. 1998 Apr; 16(8):1301-9. PMID: 9777604.
    Citations: 4     Fields:    Translation:Animals
  127. Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res. 1998 Feb; 4(2):317-24. PMID: 9516917.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  128. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55. PMID: 8993518.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  129. Supko JG, Phillips LR, Malspeis L. Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma. J Chromatogr B Biomed Appl. 1996 Mar 03; 677(2):351-62. PMID: 8704941.
    Citations: 1     Fields:    Translation:HumansAnimals
  130. Rice WG, Supko JG, Malspeis L, Buckheit RW, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, Gogliotti R, Bader JP, Halliday SM, Coren L, Sowder RC, Arthur LO, Henderson LE. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science. 1995 Nov 17; 270(5239):1194-7. PMID: 7502043.
    Citations: 76     Fields:    Translation:HumansAnimalsCells
  131. Supko J, Malspeis L. Plasma pharmacokinetics of genistein in mice. Int J Oncol. 1995 Oct; 7(4):847-54. PMID: 21552913.
    Citations: 11     Fields:    
  132. Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, Sausville EA. Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res. 1995 Jul 01; 55(13):2794-9. PMID: 7796405.
    Citations: 6     Fields:    Translation:HumansCells
  133. Phillips LR, Malspeis L, Supko JG. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog. Drug Metab Dispos. 1995 Jul; 23(7):676-80. PMID: 7587953.
    Citations: 7     Fields:    Translation:Animals
  134. Supko JG, Phillips LR. High-performance liquid chromatographic assay for genistein in biological fluids. J Chromatogr B Biomed Appl. 1995 Apr 07; 666(1):157-67. PMID: 7655614.
    Citations:    Fields:    Translation:Animals
  135. Supko JG, Malspeis L. Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog. Antimicrob Agents Chemother. 1995 Jan; 39(1):9-14. PMID: 7695336; PMCID: PMC162476.
    Citations: 1     Fields:    Translation:AnimalsCells
  136. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36(4):305-15. PMID: 7628050.
    Citations: 136     Fields:    Translation:HumansAnimalsCells
  137. Supko JG, Malspeis L. Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother Pharmacol. 1994; 33(4):325-30. PMID: 8281627.
    Citations: 8     Fields:    Translation:Animals
  138. Supko JG, Malspeis L. Determination of michellamine B in biological fluids by high-performance liquid chromatography with fluorescence detection. Anal Biochem. 1994 Jan; 216(1):52-60. PMID: 8135366.
    Citations: 1     Fields:    Translation:HumansAnimals
  139. Supko JG, Balcerzak SP, Kraut EH. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Cancer Res. 1993 Oct 15; 53(20):4843-9. PMID: 8402671.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  140. Supko JG, Malspeis L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res. 1993 Jul 01; 53(13):3062-9. PMID: 8319213.
    Citations: 11     Fields:    Translation:Animals
  141. Phillips LR, Supko JG, Malspeis L. Analysis of brefeldin A in plasma by gas chromatography with electron capture detection. Anal Biochem. 1993 May 15; 211(1):16-22. PMID: 8323029.
    Citations: 5     Fields:    Translation:Animals
  142. Supko JG, Malspeis L. Characterization of the urinary metabolites of merbarone in cancer patients. Drug Metab Dispos. 1991 Jan-Feb; 19(1):263-73. PMID: 1673412.
    Citations:    Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Supko's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (510)
Co-Authors (158)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.